During the past decade, Emory Univ. Hemophilia Program Office conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emory Univ. Hemophilia Program Office" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator and "Glaxo Wellcome" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Emory Univ. Hemophilia Program Office" are "HIV Infections" (4 trials) and "Pneumonia, Pneumocystis Carinii" (1 trials). Many other conditions were trialed in "Emory Univ. Hemophilia Program Office" in a lesser frequency.

Most popular intervention types in "Emory Univ. Hemophilia Program Office" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Didanosine" (2 trials), "Lamivudine" (2 trials), "Zidovudine" (2 trials), "Atovaquone" (1 trials) and "Dapsone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Emory Univ. Hemophilia Program Office" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Emory Univ. Hemophilia Program Office". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Emory Univ. Hemophilia Program Office, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Emory Univ. Hemophilia Program Office, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".